Short Interest in Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Grows By 203.0%

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) saw a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 229,817 shares, a growth of 203.0% from the January 15th total of 75,842 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,165,477 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily trading volume, of 1,165,477 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Separately, Zacks Research cut Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

Daiichi Sankyo Stock Performance

Shares of DSNKY traded up $0.33 on Friday, reaching $19.09. The company’s stock had a trading volume of 6,993 shares, compared to its average volume of 691,897. The stock has a market capitalization of $36.16 billion and a P/E ratio of 16.75. Daiichi Sankyo has a 12-month low of $17.80 and a 12-month high of $28.21. The stock’s 50 day simple moving average is $20.86 and its two-hundred day simple moving average is $23.18. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.69 and a quick ratio of 1.85.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its quarterly earnings results on Thursday, January 29th. The company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.05. Daiichi Sankyo had a return on equity of 18.39% and a net margin of 15.40%.The business had revenue of $3.65 billion for the quarter, compared to the consensus estimate of $3.88 billion. Research analysts forecast that Daiichi Sankyo will post 0.73 earnings per share for the current fiscal year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.